A Phase 3 interventional study of Orforglipron and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 70 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 9th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 6 started in 2023.
This study's enrollment of 546 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 53rd largest by enrollment of the 232 interventional ones that give a count, is one of 17 that started in 2023, is one of 85 in phase 3, and was the 204th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have been treated with stable doses of the same formulation of the following for ≥90 days prior to screening visit 1 and have maintained the same doses through randomization:
Exclusion Criteria:
Have had any of the following cardiovascular conditions within 60 days prior to baseline.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo administered orally once daily (QD) and insulin glargine therapy (100 Units per milliliter (U/mL)) administered subcutaneously (SC) QD, over a period of 40 weeks.
Drug: Placebo
Participants received oral orforglipron, initiated at 1 milligram (mg) and increased every 4 weeks until reaching to a maintenance dose of 3 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.
Drug: Orforglipron
Participants received oral orforglipron, initiated at 1 mg and increasing every 4 weeks until reaching to a maintenance dose of 12 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.
Drug: Orforglipron
Participants received oral orforglipron, initiated at 1 mg and increasing every 4 weeks until reaching to a maintenance dose of 36 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.
Drug: Orforglipron
Administered orally.
Also known as: LY3502970
Administered orally.
Change From Baseline in Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)
Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
Time frame: Week 40
Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)
Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
Time frame: Week 40
Change From Baseline in Fasting Serum Glucose (FSG)
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Body Weight
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Body Weight (kg)
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Triglycerides
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Systolic Blood Pressure (mmHg)
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Daily Insulin Glargine Dose (IU/Day)
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
Time frame: Week 40
Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
Time frame: Week 40
Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
Time frame: Week 40
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 40
| Milestone | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Started | 141 | 137 | 132 | 136 |
| All randomised participants | 141 | 137 | 132 | 136 |
| All randomised participants who received at least 1 dose of the study intervention | 140 | 137 | 132 | 135 |
| Completed | 131 | 131 | 124 | 121 |
| Not completed | 10 | 6 | 8 | 15 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 | 6 |
| Withdrew: Adverse event | 2 | 2 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 3 |
| Withdrew: Physician decision | 1 | 0 | 3 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| percentage of HbA1c | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.77 ± 0.078 | -1.54 ± 0.097 | -2.05 ± 0.098 | -1.90 ± 0.111 |
Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
| Percentage of participants | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol) | 23.69 | 60.74 | 80.76 | 69.16 |
Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
| percentage of participants | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol) | 11.09 | 45.94 | 69.12 | 60.07 |
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| milligrams per deciliter (mg/dL) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -35.3 ± 2.36 | -40.5 ± 2.84 | -48.0 ± 2.74 | -44.5 ± 2.69 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| Percent change | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight | 0.6 ± 0.44 | -2.7 ± 0.52 | -5.8 ± 0.58 | -6.1 ± 0.68 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| Kilogram (kg) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Body Weight (kg) | 0.5 ± 0.39 | -2.2 ± 0.48 | -5.0 ± 0.49 | -5.2 ± 0.64 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| Percent change | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol | -1.13 ± 2.679 | -3.90 ± 2.346 | -7.64 ± 2.597 | -7.81 ± 2.450 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| Percent change | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides | -4.73 ± 3.398 | -4.80 ± 3.149 | -17.45 ± 3.040 | -14.71 ± 3.144 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (mmHg) | 0.0 ± 1.03 | -1.9 ± 0.94 | -3.2 ± 1.13 | -2.2 ± 1.26 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.
| International Units per day (IU/day) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Daily Insulin Glargine Dose (IU/Day) | 21.4 ± 2.41 | 8.9 ± 1.57 | 10.2 ± 1.89 | 8.4 ± 2.28 |
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
| percentage of participants | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction | 16.10 | 35.42 | 52.61 | 50.56 |
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
| percentage of participants | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction | 4.24 | 15.70 | 23.34 | 27.38 |
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].
| percentage of participants | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction | 2.52 | 6.18 | 9.90 | 14.12 |
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| t-score | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Physical Component Score | 0.71 ± 0.491 | 0.47 ± 0.496 | 1.07 ± 0.592 | 0.35 ± 0.572 |
| Mental Component Score | 0.13 ± 0.673 | 1.11 ± 0.693 | 0.19 ± 0.700 | 0.98 ± 0.514 |
Collected over Baseline to end of safety follow-up (up to 42 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/140 (0%) | 6/140 (4.3%) | 111/140 (79.3%) |
| 3 mg Orforglipron QD | 0/137 (0%) | 7/137 (5.1%) | 110/137 (80.3%) |
| 12 mg Orforglipron QD | 0/132 (0%) | 9/132 (6.8%) | 105/132 (79.5%) |
| 36 mg Orforglipron QD | 1/135 (0.7%) | 10/135 (7.4%) | 114/135 (84.4%) |
| Event | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/140 | 0/137 | 2/132 | 0/135 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/140 | 0/137 | 2/132 | 1/135 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/65 | 0/72 | 0/77 | 1/73 |
| Angina unstableCardiac disorders | 0/140 | 0/137 | 1/132 | 0/135 |
| Coronary artery diseaseCardiac disorders | 0/140 | 0/137 | 1/132 | 0/135 |
| InfluenzaInfections and infestations | 0/140 | 0/137 | 1/132 | 0/135 |
| Urinary tract infectionInfections and infestations | 0/140 | 0/137 | 1/132 | 0/135 |
| Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders | 0/140 | 0/137 | 1/132 | 0/135 |
| Salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/140 | 0/137 | 1/132 | 0/135 |
| HypoaesthesiaNervous system disorders | 0/140 | 0/137 | 1/132 | 0/135 |
| Event | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/140 | 29/137 | 37/132 | 41/135 |
| Diabetic retinopathyEye disorders | 39/140 | 24/137 | 21/132 | 32/135 |
| VomitingGastrointestinal disorders | 0/140 | 11/137 | 20/132 | 29/135 |
| Decreased appetiteMetabolism and nutrition disorders | 6/140 | 19/137 | 21/132 | 28/135 |
| DiarrhoeaGastrointestinal disorders | 10/140 | 26/137 | 18/132 | 22/135 |
| ConstipationGastrointestinal disorders | 6/140 | 20/137 | 15/132 | 10/135 |
| Lipase increasedInvestigations | 4/140 | 6/137 | 12/132 | 13/135 |
| DyspepsiaGastrointestinal disorders | 4/140 | 8/137 | 12/132 | 8/135 |
| Blood creatine phosphokinase increasedInvestigations | 2/140 | 6/137 | 6/132 | 12/135 |
| InfluenzaInfections and infestations | 12/140 | 2/137 | 2/132 | 7/135 |
All randomised participants.
| Age, Categorical(Participants) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 87 | 94 | 80 | 88 | 349 |
| >=65 years | 54 | 43 | 52 | 48 | 197 |
| Sex: Female, Male(Participants) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Female | 75 | 65 | 55 | 62 | 257 |
| Male | 66 | 72 | 77 | 74 | 289 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 59 | 53 | 55 | 59 | 226 |
| Not Hispanic or Latino | 82 | 83 | 77 | 77 | 319 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 0 | 2 |
| Asian | 36 | 35 | 33 | 36 | 140 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 13 | 15 | 12 | 13 | 53 |
| White | 82 | 80 | 77 | 80 | 319 |
| More than one race | 5 | 5 | 7 | 6 | 23 |
| Unknown or Not Reported | 4 | 2 | 2 | 0 | 8 |
| Region of Enrollment(participants) | Placebo | 3 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Romania | 33 | 32 | 31 | 30 | 126 |
| United States | 26 | 26 | 26 | 27 | 105 |
| Japan | 19 | 18 | 18 | 18 | 73 |
| China | 17 | 16 | 14 | 17 | 64 |
| Brazil | 46 | 45 | 43 | 44 | 178 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2023 to primary completion in Sep 2025, 22 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron